» Articles » PMID: 18193359

Vasculitis: Current Status and Future Directions

Overview
Date 2008 Jan 15
PMID 18193359
Authors
Affiliations
Soon will be listed here.
Abstract

Vasculitides represent such a heterogeneous group of disorders that difficulties arise in their classification. Although biopsy examination of involved tissues remains essential, new serological markers have been developed. Therapeutic strategies have been refined, and B lymphocyte-targeted drugs may prove a satisfactory alternative.

References
1.
Taylor D . Pharmacogenetics of beta2-agonist drugs in asthma. Clin Rev Allergy Immunol. 2006; 31(2-3):247-58. DOI: 10.1385/CRIAI:31:2:247. View

2.
Haney S, Hancox R . Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol. 2006; 31(2-3):181-96. DOI: 10.1385/CRIAI:31:2:181. View

3.
Csernok E, Moosig F, Gross W . Pathways to ANCA production: from differentiation of dendritic cells by proteinase 3 to B lymphocyte maturation in Wegener's granuloma. Clin Rev Allergy Immunol. 2008; 34(3):300-6. DOI: 10.1007/s12016-007-8056-8. View

4.
Smart B . Is rhinosinusitis a cause of asthma?. Clin Rev Allergy Immunol. 2006; 30(3):153-64. DOI: 10.1385/CRIAI:30:3:153. View

5.
Toubi E . The role of CD4+CD25+ T regulatory cells in autoimmune diseases. Clin Rev Allergy Immunol. 2007; 34(3):338-44. DOI: 10.1007/s12016-007-8043-0. View